{"id":"NCT02660580","sponsor":"Fresenius Kabi SwissBioSim GmbH","briefTitle":"MSB11022 in Moderate to Severe Chronic Plaque Psoriasis","officialTitle":"A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira® in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-16","primaryCompletion":"2016-12-31","completion":"2017-12-18","firstPosted":"2016-01-21","resultsPosted":"2019-02-19","lastUpdate":"2023-12-27"},"enrollment":443,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis","Plaque Type Psoriasis","Moderate to Severe Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"MSB11022","otherNames":[]},{"type":"DRUG","name":"Humira®","otherNames":[]}],"arms":[{"label":"MSB11022 (Core Treatment Period)","type":"EXPERIMENTAL"},{"label":"EU-Humira","type":"ACTIVE_COMPARATOR"},{"label":"MSB11022 (Extended Treatment Period)","type":"EXPERIMENTAL"},{"label":"EU-Humira/EU-Humira","type":"ACTIVE_COMPARATOR"},{"label":"EU-Humira/MSB11022","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"MSB11022 (Core Treatment Period)","deltaMin":89.7,"sd":null},{"arm":"EU-Humira","deltaMin":91.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":76,"countries":["United States","Bulgaria","Canada","Czechia","Estonia","France","Germany","Hungary","Mexico","Poland","Russia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":221},"commonTop":["Nasopharyngitis","Injection site erythema","Injection site pain","Psoriasis","Upper respiratory tract infection"]}}